IP Verse

Toxicity Management For Anti-Tumor Activity Of Cars - EP3338794

The patent EP3338794 was granted to The Childrens Hospital OF Philadelphia on Feb 26, 2020. The application was originally filed on Jul 12, 2013 under application number EP18154090A. The patent is currently recorded with a legal status of "Revoked".

EP3338794

THE CHILDRENS HOSPITAL OF PHILADELPHIA
Application Number
EP18154090A
Filing Date
Jul 12, 2013
Status
Revoked
Jun 30, 2023
Publication Date
Feb 26, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (9)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SECERNANov 26, 2020SECERNAADMISSIBLE
STRAWMANNov 26, 2020VOSSIUS & PARTNERADMISSIBLE
STRAWMANNov 26, 2020VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBBADMISSIBLE
WEINZIERLNov 26, 2020SCHIWECK WEINZIERL KOCHADMISSIBLE
WEINZIERLNov 26, 2020SCHIWECK WEINZIERL KOCH PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE
ZWICKER SCHNAPPAUF & PARTNERNov 26, 2020-ADMISSIBLE
GEDEON RICHTER PHARMANov 25, 2020MAIWALDADMISSIBLE
HOFFMANN EITLENov 25, 2020HOFFMANN EITLEADMISSIBLE
BOULT WADE TENNANTNov 13, 2020BOULT WADE TENNANTADMISSIBLE

Patent Citations (24) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2011US64191
DESCRIPTIONUS2006251653
DESCRIPTIONUS5199942
DESCRIPTIONUS5225539
DESCRIPTIONUS5530101
DESCRIPTIONUS5585089
DESCRIPTIONUS5693761
DESCRIPTIONUS5693762
DESCRIPTIONUS6120766
DESCRIPTIONUS6267722
DESCRIPTIONUS6656745
DESCRIPTIONUS6818455
DESCRIPTIONUS7189522
DESCRIPTIONWO9007861
DESCRIPTIONWO9117271
DESCRIPTIONWO9201047
DESCRIPTIONWO9312227
OPPOSITIONWO2005023761
OPPOSITIONWO2008144763
OPPOSITIONWO2011066371
OPPOSITIONWO2012079000
OPPOSITIONWO2013033626
OPPOSITIONWO2014011984
SEARCHWO2005023761

Non-Patent Literature (NPL) Citations (153) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- BARGOU et al., Science, (20080000), vol. 321, pages 974 - 977
DESCRIPTION- BARRETT et al., N Engl J Med, (19940000), vol. 331, pages 1253 - 1258
DESCRIPTION- BEHRENS et al., J Clin Invest, (20110000), vol. 121, no. 6, pages 2264 - 2277
DESCRIPTION- BIERER et al., Curr. Opin. Immun., (19930000), vol. 5, pages 763 - 773
DESCRIPTION- BIRD et al., Science, (19880000), vol. 242, pages 423 - 426
DESCRIPTION- BOYCE et al., Annals of Oncology, (20030000), vol. 14, pages 520 - 535
DESCRIPTION- BRENTJENS et al., Blood, (20110000), vol. 118, pages 4817 - 4828
DESCRIPTION- COLLINS et al., Bone Marrow Transplant, (20000000), vol. 26, no. 5, pages 511 - 516
DESCRIPTION- COLLINS et al., J Clin Oncol, (19970000), vol. 15, pages 433 - 444
DESCRIPTION- DROBYSKI et al., Biol Blood Marrow Transplant, (20110000), vol. 17, no. 12, pages 1862 - 1868
DESCRIPTION- GARCIA-MANERO; THOMAS, Hematol Oncol Clin North Am, (20010000), vol. 15, no. 1, pages 163 - 205
DESCRIPTION- GOKBUGET et al., Blood, (20120000), vol. 120, pages 2032 - 2041
DESCRIPTION- GOUJON et al., Nucleic Acids Res, (20100000), vol. 38, pages 695 - 699
DESCRIPTION- HENDERSON et al., Immun., (19910000), vol. 73, pages 316 - 321
DESCRIPTION- HOTFILDER et al., Cancer Research, (20050000), vol. 65, pages 1442 - 1449
DESCRIPTION- HOUSTON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, pages 5879 - 5883
DESCRIPTION- HUSE et al., Science, (19890000), vol. 246, pages 1275 - 1281
DESCRIPTION- JANKA et al., Annu Rev Med, (20120000), vol. 63, pages 233 - 246
DESCRIPTION- JENSEN et al., Biol Blood Marrow Transplant, (20100000), vol. 16, pages 1245 - 1256
DESCRIPTION- KALOS et al., Science Translational Medicine, (20110000), vol. 3, page 95ra73
DESCRIPTION- KOCHENDERFER et al., Blood, (20100000), vol. 116, pages 4099 - 4102
DESCRIPTION- KOCHENDERFER et al., Blood, (20120000), vol. 119, pages 2709 - 2720
DESCRIPTION- KOHLER; MILSTEIN, Nature, (19750000), vol. 256, pages 495 - 497
DESCRIPTION- KOLB et al., Blood, (19950000), vol. 86, pages 2041 - 2050
DESCRIPTION- LARIMORE et al., J Immunol, (20120000), vol. 189, pages 3221 - 3230
DESCRIPTION- LE HUU et al., J Invest Dermatol, (20120000), vol. 132, no. 12, pages 2752 - 2761
DESCRIPTION- LE VISEUR et al., Cancer Cell, (20080000), vol. 14, pages 47 - 58
DESCRIPTION- LIU et al., Cell, (19910000), vol. 66, pages 807 - 815
DESCRIPTION- MILONE et al., Mol Ther, vol. 17, pages 1453 - 1464
DESCRIPTION- OLSON et al., J Transl Med, (20110000), vol. 9, page 26
DESCRIPTION- PORTER et al., N Engl J Med, (20110000), vol. 365, pages 725 - 733
DESCRIPTION- PULLEN et al., J Clin Oncol, (19930000), vol. 11, no. 5, pages 839 - 849
DESCRIPTION- QUEEN et al., Proc. NatL. Acad. Sci. USA, (19890000), vol. 86, pages 10029 - 10033
DESCRIPTION- ROBINS et al., Blood, (20090000), vol. 114, pages 4099 - 4107
DESCRIPTION- ROSENBERG et al., New Eng. J. of Med., (19880000), vol. 319, page 1676
DESCRIPTION- SAVOLDO et al., J Clin Invest, (20110000), vol. 121, pages 1822 - 1825
DESCRIPTION- SIEVERS et al., Mol Syst Biol, (20110000), vol. 7, page 539
DESCRIPTION- TANG et al., Br J Haematol, (20080000), vol. 143, pages 84 - 91
DESCRIPTION- TAWARA et al., Clinical Cancer Research, (20110000), vol. 17, pages 77 - 88
DESCRIPTION- TILL et al., Blood, (20080000), vol. 112, pages 2261 - 2271
DESCRIPTION- TILL et al., Blood, (20120000), vol. 119, pages 3940 - 3950
DESCRIPTION- WARD et al., Nature, (19890000), vol. 341, pages 544 - 546
OPPOSITION- Anandani Nellan, "Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques", Blood, (20180628), pages 662 - 666, Blood, URL: https://ashpublications.org/blood/article/132/6/662/39412/Improved-CNS-exposure-to-tocilizumab-after, (20201218), XP055761286
OPPOSITION- Anonymous, "Cytokine Storm", Wikipedia, the free encyclopedia, (20120605), URL: https://en.wikipedia.org/wiki/Cytokine_storm, XP055760332
OPPOSITION- Common Terminology Criteria for Adverse Events (CTCAE, (20100600), pages 1 - 196
OPPOSITION- "Common Terminology Criteria for Adverse Events (CTCAE)", (20100614), XP055307936
OPPOSITION- EMA, "EMA Assessment Report for RoActemra", EMEA/26276/2009, (20090200), pages 1 - 55, URL: https://www.ema.europa.eu/en/documents/assessment-report/roactemra-epar-public-assessment-report_en.pdf, XP055760290
OPPOSITION- GRADY Denise, "In Girl's Last Hope, Altered Immune Cells Beat Leukemia", The New York Times, (20121209), URL: https://www.nytimes.com/2012/12/10/health/a-breakthrough-against-leukemia-using-altered-t-cells.html, XP055760303
OPPOSITION- J Kamarashev, Et Al, "Generalised Pustular Psoriasis Induced by Cyclosporin A Withdrawal Responding to the Tumour Necrosis Factor Alpha Inhibitor Etanercept", Dermatology, (20020101), vol. 205, pages 213 - 216, XP055763376
OPPOSITION- Juan E Losa Garcia, Et Al, "Cyclosporin A decreases human macrophage interleukin-6 synthesis at post-transcriptional level", Mediators of Inflammation, (19990101), vol. 8, pages 253 - 259, XP055763385
OPPOSITION- Kathleen M. Coyle, "Actemra® (tocilizumab)", Clinical Review, (20110416), pages 1 - 97, URL: https://www.fda.gov/media/80457/download, XP055763020
OPPOSITION- Kazusa Ishii, "Tocilizumab-Refractory Cytokine Release Syndrome (CRS) Triggered By Chimeric Antigen Receptor (CAR)-Transduced T Cells May Have Distinct Cytokine Profiles Compared to Typical CRS", blood, (20161202), vol. 128, no. 22, page 3358, XP055761120
OPPOSITION- Lee, S. ; Ballow, M., "Monoclonal antibodies and fusion proteins and their complications: Targeting B cells in autoimmune diseases", Journal of Allergy and Clinical Immunology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20100401), vol. 125, no. 4, ISSN 0091-6749, pages 814 - 820, XP026988731
OPPOSITION- LEE S. et al., "Monoclonal antibodies and fusion proteins and their complications: Targeting B cells in autoimmune diseases", J Allergy Clin Immunol, (20100400), vol. 125, no. 4, pages 814 - 20, XP026988731
OPPOSITION- "Leukemia patients remain in remission more than two years after engineered T cell therapy", (20121210), XP055763023
OPPOSITION- Mark Fuerst, "CAR Update Genetically Engineered T-cell Therapy Induces Durable Responses in Refractory Leukemias", Oncology Times, (20130225), pages 20 - 21, XP055763420
OPPOSITION- Martine Szyper-Kravitz, "The hemophagocytic syndrome/macrophage activation syndrome: a final common pathway of a cytokine storm", IMAJ, Israel Medical Association, IR, IR, (20091001), vol. 11, no. 10, ISSN 1565-1088, pages 633 - 634, XP055763019
OPPOSITION- Noelle V Frey, "Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells", Blood, (20140101), page 2296, Blood, URL: https://ashpublications.org/blood/article/124/21/2296/89770/Refractory-Cytokine-Release-Syndrome-in-Recipients, (20201217), XP055761101
OPPOSITION- Sha Beverly E et al, "Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2", AIDS RESEARCH AND HUMAN RETROVIRUSES., MARY ANN LIEBERT., US, US, (20020610), vol. 18, no. 9, ISSN 0889-2229, pages 661 - 665, XP009117547
OPPOSITION- SZYPER-KRAVITZ, M. et al., "The Hemophagocytic Syndrome/Macrophage Activation Syndrome: A Final Common Pathway of a Cytokine Storm", The Israel Medical Association Journal, (20091000), vol. 11, pages 633 - 634, XP055763019
OPPOSITION- VADHAN-RAJ et al., "Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome", Blood, (20090000), vol. 114, page 105
OPPOSITION- WAGNER et al., "CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?", Mol Ther, (20201104), vol. 28, no. 11, pages 2320 - 2339, XP055760310
OPPOSITION- WINKLER U et al., "Cytokine-Release Syndrome in Patients with B- Cell Chronic Lymphocytic Leukemia and High Lymphocyte Count After Treatment with Anti- CD 20 Monoclonal Antibody (Rituximab, IDEC-C2B8", Blood, (19990000), vol. 94, no. 7, pages 2217 - 2224, XP001022211
OPPOSITION- WINKLER U, ET AL., "CYTOKINE-RELEASE SYNDROME IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA AND HIGH LYMPHOCYTE COUNTS AFTER TREATMENT WITH AN ANTI-CD20 MONOCLONAL ANTIBODY (RITUXIMAB, IDEC-C2B8)", Blood, (19991001), vol. 94, no. 07, ISSN 0006-4971, pages 2217 - 2224, XP001022211
OPPOSITION- BRANDL C. et al., "The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct", Cancer Immunol Immunother, (20070720), vol. 56, no. 10, pages 1551 - 1563, XP019539092
OPPOSITION- LIPOWSKA-BHALLA et al., "Targeted immunotherapy of cancer with CAR T cells: achievements and challenges", Cancer Immunol Immunother, (20120422), vol. 61, no. 7, pages 953 - 962, XP035074376
OPPOSITION- Amita Aggarwal, Ramnath Misra, "Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis", Rheumatology International: clinical and experimental investigations, Springer, DE, DE, (20030501), vol. 23, no. 3, doi:10.1007/s00296-002-0267-y, ISSN 0172-8172, pages 134 - 137, XP055763387
OPPOSITION- Andreas Reiff, "Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment", Biologics in Therapy, (20120101), vol. 2, no. 1, doi:10.1007/s13554-012-0001-6, XP055763396
OPPOSITION- DROBYSKI W. R. et al., "Tocilizumab for the treatment of steroid refractory graft-versus- host disease", Biol Blood Marrow Transplant, (20111200), vol. 17, pages 1862 - 1868, XP028112518
OPPOSITION- William R. Drobysk et al, "Tocilizumab for the Treatment of Steroid Refractory Graft-versus-Host Disease", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, KLUGE CARDEN JENNINGS PUBLISHING, CHARLOTTESVILLE, VA, US, US, (20110705), vol. 17, no. 12, doi:10.1016/j.bbmt.2011.07.001, ISSN 1083-8791, pages 1862 - 1868, XP028112518
OPPOSITION- William R. Drobyski et al, "Tocilizumab for the Treatment of Steroid Refractory Graft-versus-Host Disease", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, KLUGE CARDEN JENNINGS PUBLISHING, CHARLOTTESVILLE, VA, US, US, (20110705), vol. 17, no. 12, doi:10.1016/j.bbmt.2011.07.001, ISSN 1083-8791, pages 1862 - 1868, XP028112518
OPPOSITION- MARTIN Paul J. et al., "First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation Authors:", Biol Blood Marrow Transplant, (20120410), vol. 18, no. 8, pages 1150 - 1163, XP028432150
OPPOSITION- TANAKA et al., "Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases", FEBS Letters, (20110000), vol. 585, doi:10.1016/j.febslet.2011.03.023, pages 3699 - 3709, XP028118458
OPPOSITION- NOGUCHI et al., "Blockade of IL-6-signaling inhibits the pathogenesis of CD4+ T cell-mediated lethal graft-versus-host reaction against minor histocompatibility antigen", Immunol Lett, (20110108), vol. 136, no. 2, pages 146 - 155, XP028370301
OPPOSITION- FERRARA et al., "Graft-versus-host disease", Lancet, (20090502), vol. 373, no. 9674, pages 1550 - 1561, XP055760329
OPPOSITION- FERRARA, J.L.M. et al., "Graft-versus Host Disease", Lancet, (20090502), vol. 373, no. 9674, pages 1550 - 1561, XP026088702
OPPOSITION- Kaplanski, G. Marin, V. Montero-Julian, F. Mantovani, A. Farnarier, C., "IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation", TRENDS IN IMMUNOLOGY, Elsevier Ltd. * Trends Journals, GB, GB, (20030101), vol. 24, no. 1, doi:10.1016/S1471-4906(02)00013-3, ISSN 1471-4906, pages 25 - 29, XP004398541
OPPOSITION- RAVELLI et al., "Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment", Genes and Immunity, (20120315), vol. 13, no. 4, pages 289 - 298, XP055760284
OPPOSITION- Doanh Le Huu, Et Al, "IL-6 Blockade Attenuates the Development of Murine Sclerodermatous Chronic Graft-Versus-Host Disease", Journal of Investigative Dermatology, Elsevier, NL, NL, (20121201), vol. 132, no. 12, doi:10.1038/jid.2012.226, ISSN 0022-202X, pages 2752 - 2761, XP055763411
OPPOSITION- MORGAN et al., "Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2", Molecular Therapy, (20100000), vol. 18, doi:10.1038/mt.2010.24, pages 843 - 851, XP055023624
OPPOSITION- MORGAN et al., "Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2", Molecular Therap y, (20100000), vol. 18, no. 4, doi:10.1038/mt.2010.24, pages 843 - 851, XP055023624
OPPOSITION- MORGAN et al., "Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2", Mol Ther, (20100401), vol. 18, no. 4, pages 843 - 851, XP055023624
OPPOSITION- MORGAN, R. A. et al., "Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced with a Chimeric Antigen Receptor Recognizing Erbb2", Molecular Therapy, (20100400), vol. 18, no. 4, pages 843 - 851, XP055023624
OPPOSITION- Richard A Morgan et al, "Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2", Molecular Therapy, No longer published by Elsevier, (20100401), vol. 18, no. 4, doi:10.1038/mt.2010.24, ISSN 1525-0016, pages 843 - 851, XP055023624
OPPOSITION- Jianshu Wei et al, "The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma", Signal Transduction and Targeted Therapy, (20201201), vol. 5, no. 1, doi:10.1038/s41392-020-00256-x, XP055761280
OPPOSITION- LIU et al., "Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia", Blood Cancer J, (20200102), vol. 10, no. 2, page 15, XP055696809
OPPOSITION- SUNTHARALINGAM GANESH, ET AL, "Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412", New England Journal of Medicine, New England Journal of Medicine, (20060907), vol. 355, no. 10, doi:10.1056/NEJMoa063842, ISSN 0028-4793, pages 1018 - 1028, XP002559375
OPPOSITION- David L. Porter et al, "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia", New England Journal of Medicine, New England Journal of Medicine, (20110825), vol. 365, no. 8, doi:10.1056/NEJMoa1103849, ISSN 0028-4793, pages 725 - 733, XP002732435
OPPOSITION- PORTER David L. et al., "Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia", N Eng J Med, (20110825), vol. 365, no. 8, pages 725 - 733, XP055579937
OPPOSITION- PORTER, D.L. et al., "Chimeric Antigen Receptor-Modified T cells in Chronic Lymphoid Leukemia", New England Journal of Medicine, (20110825), vol. 365, no. 8, pages 725 - 733, XP002732435
OPPOSITION- PORTER et al., "Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia", The New England Journal of Medicine, (20110000), vol. 365, doi:10.1056/NEJMoa1103849, pages 725 - 733, XP055579937
OPPOSITION- GRUPP et al., "Chimeric Antigen Receptor- Modified T Cells for Acute Lymphoid Leukemia", The New England Journal of Medicine, (20130325), vol. 368, no. 16, doi:10.1056/NEJMoa1215134, pages 1509 - 1518, XP055169041
OPPOSITION- GRUPP S.A. et al., "Chimeric Antigen Receptor-Modified T cells for Acute Lymphoid Leukemia", New England Journal of Medicine, (20130418), vol. 368, no. 16, pages 1509 - 1518, XP055169041
OPPOSITION- GRUPP S. et al., "Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia", N Eng J Med, (20130418), vol. 368, no. 16, pages 1509 - 1518, XP055169041
OPPOSITION- Stephan A. Grupp et al, "Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia", New England Journal of Medicine, New England Journal of Medicine, (20130418), vol. 368, no. 16, doi:10.1056/NEJMoa1215134, ISSN 0028-4793, pages 1509 - 1518, XP055169041
OPPOSITION- HOWARD et al., "The Tumor Lysis Syndrome", N Eng J Med, (20110512), vol. 364, no. 19, pages 1844 - 1854, XP055253813
OPPOSITION- ESHHAR Z. et al., "Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors", PNAS, (19930000), vol. 90, pages 720 - 724, XP002009770
OPPOSITION- SHA et al., "Effect of Etanercept (Enbrel) on Interleukin 6, Tumor Necrosis Factor a, and Markers of Immune Activation in HIV-Infected Subjects Receiving Interleukin 2", AIDS Research and Human Retroviruses, (20020000), vol. 18, doi:10.1089/088922202760019365, pages 661 - 665, XP002529874
OPPOSITION- DOTTI G. et al., "Fifteen Years of Gene Therapy Based on Chimeric Antigen Receptors: ''Are We Nearly There Yet?''", Human Gene Therapy, (20090922), vol. 20, no. 11, pages 1229 - 1239, XP055122213
OPPOSITION- Alexander Krüttgen, Stefan Rose-John, "Interleukin-6 in Sepsis and Capillary Leakage Syndrome", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH., MARY ANN LIEBERT, NEW YORK, NY., US, US, (20120201), vol. 32, no. 2, doi:10.1089/jir.2011.0062, ISSN 1079-9907, pages 60 - 65, XP055763364
OPPOSITION- Lucrecia Yáñez, Miriam Sánchez-Escamilla, Miguel-Angel Perales, "CAR T Cell Toxicity: Current Management and Future Directions", HemaSphere, (20190401), vol. 3, no. 2, doi:10.1097/HS9.0000000000000186, page e186, XP055763414
OPPOSITION- MAUDE S. et al., "Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies", Cancer J, (20140101), vol. 20, no. 2, pages 119 - 122, XP055188104
OPPOSITION- KALOS et al., "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", Science Translational Medicine, (20110000), vol. 3, no. 95, doi:10.1126/scitranslmed.3002842, pages 95 - 73, 1-11, XP002667262
OPPOSITION- KALOS M. et al., "T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia", Science of Translational Medicine, (20110810), vol. 3, no. 95, pages 95ra73.1 - 95ra73.11, XP002667262
OPPOSITION- KALOS M. et al., "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", Sci Transl Med, (20110810), vol. 3, no. 95, pages 95ra73.1 - 95ra73.11, XP002667262
OPPOSITION- KALOS MICHAEL, ET AL, "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", (20110810), vol. 3, no. 95, doi:10.1126/scitranslmed.3002842, pages 1 - 13, XP002667262
OPPOSITION- J. R. Tisoncik et al, "Into the Eye of the Cytokine Storm", Microbiology and Molecular Biology Reviews, American Society for Microbiology (ASM), (20120301), vol. 76, no. 1, doi:10.1128/MMBR.05015-11, ISSN 10922172, pages 16 - 32, XP055183762
OPPOSITION- Atsushi Ogata, Toshio Tanaka, "Tocilizumab for the Treatment of Rheumatoid Arthritis and Other Systemic Autoimmune Diseases: Current Perspectives and Future Directions", International Journal of Rheumatology, (20120101), vol. 2012, doi:10.1155/2012/946048, ISSN 1687-9260, pages 1 - 14, XP055763394
OPPOSITION- Isao Tawara et al, "Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation", CLINICAL CANCER RESEARCH, American Association for Cancer Research, US, US, (20110101), vol. 17, no. 1, doi:10.1158/1078-0432.CCR-10-1198, ISSN 1078-0432, pages 77 - 88, XP055763021
OPPOSITION- TAWARA I et al., "Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.", Clin Cancer Res., (20111103), vol. 17, pages 77 - 88, XP055763021
OPPOSITION- CHINNASAMY D. et al., "Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice", Clin Cancer Res, (20120130), vol. 18, no. 6, pages 1672 - 83, XP055185300
OPPOSITION- Juliane Gust et al, "Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells", CANCER DISCOVERY, American Association for Cancer Research, US, US, (20180326), vol. 7, no. 12, doi:10.1158/2159-8290.CD-17-0698, ISSN 2159-8274, pages 1404 - 1419, XP055462614
OPPOSITION- JONES, S.A. et al., "Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling", J. Clinic Invest., (20110900), vol. 121, no. 9, pages 3375 - 3383, XP055265579
OPPOSITION- JONES Simon A. et al., "Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling", J Clin Invest, (20110901), vol. 121, no. 9, doi:10.1172/JCI57158, pages 3375 - 3383, XP055265580
OPPOSITION- Simon A. Jones, J�rgen Scheller, Stefan Rose-John, "Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling", The Journal of Clinical Investigation, B M J Group, GB, GB, (20110901), vol. 121, no. 9, doi:10.1172/JCI57158, ISSN 0021-9738, pages 3375 - 3383, XP055265579
OPPOSITION- BRENTJENS R.J. et al., "Safety and persistence of adoptively transferred autologous CD 19-targeted T cells in patients with relapsed or chemotherapy refractory B- cell leukemias", Blood, (20110817), vol. 118, no. 18, pages 4817 - 4828, XP055169039
OPPOSITION- J. N. Kochenderfer et al, "B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells", Blood, (20120322), vol. 119, no. 12, doi:10.1182/blood-2011-10-384388, ISSN 0006-4971, pages 2709 - 2720, XP055145503
OPPOSITION- KOCHENDERFER et al., "B- cell depletion and remissions of malignancy along with cytokine- associated toxicity in a clinical trial of anti- CD 19 chimeric-antigen-receptor-transduced T cells", Blood, (20120000), vol. 119, doi:10.1182/blood-2011-10-384388, pages 2709 - 2720, XP055145503
OPPOSITION- KOCHENDERFER James N. et al., "B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells", Blood, (20121208), vol. 119, no. 12, pages 2709 - 2720, XP055145503
OPPOSITION- KOCHENDERFER J.N. et al., "B- cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of ani- CD 19 chimeric-antigen-receptor- transduced T cells", Blood, (20111208), vol. 119, no. 12, pages 2709 - 2720, XP055145503
OPPOSITION- GRUPP et al., "CD 19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL -6 Antagonist Tocilizumab (toc", Blood, (20120000), vol. 120, doi:10.1182/blood.V120.21.2604.2604, page 2604, XP009521968
OPPOSITION- GRUPP et al., "CD 19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL -6 Antagonist Tocilizumab (toc", Blood, (20121100), vol. 12 0, no. 21, doi:10.1182/blood.V120.21.2604.2604, page 2604, XP009521968
OPPOSITION- Grupp SA. et al, "CD19-Redirected Chimeric Antigen Receptor T(CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab", Blood, (20120101), vol. 120, no. 21, doi:10.1182/blood.V120.21.2604.2604, ISSN 0006-4971, page 2604, XP009521968
OPPOSITION- GRUPP S.A. et al., "CD 19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL -6 Antagonist Tocilizumab (toc)", ASH Annual Meeting, (20121116), vol. 120, no. 21, page 2604, XP009521968
OPPOSITION- Grupp SA. Porter DL. Teachey DT, Barrett DM, Chew A. Suppa E. Levine BL Kalos M, June CH, "CD19-Redirected Chimeric Antigen Receptor T(CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab", Blood, (20120101), vol. 120, no. 21, doi:10.1182/blood.V120.21.2604.2604, ISSN 0006-4971, page 2604, XP009521968
OPPOSITION- GRUPP S. et al., "CD19-Redirected Chimeric Antigen Receptor T(CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab", Blood, (20120000), vol. 120, no. 21, page 2604, XP009521968
OPPOSITION- Porter David et al, "717: Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL", Blood, (20121116), vol. 120, no. 21, ISSN 0006-4971, page 717, XP009511066
OPPOSITION- PORTER D.L. et al., "Chimeric Antigen Receptor T Cells Directed Against CD 19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL", ASH Annual Meeting, (20121116), vol. 120, no. 21, XP009511066
OPPOSITION- PORTER D. L. et al., "Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL", Blood, (20121116), vol. 120, no. 21, page 717, XP009511066
OPPOSITION- PORTER et al., "Chimeric Antigen Receptor T Cells Directed Against CD 19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL", Blood, (20120000), vol. 120, page 717, XP009511066
OPPOSITION- PORTER et al., "Chimeric Antigen Receptor T Cells Directed Against CD 19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL", Blood, (20121100), vol. 120, no. 21, page 717, XP009511066
OPPOSITION- KALOS et al., "Sustained Functional T Cell Persistence and B Cell Aplasia Following CD 19-Targeting Adoptive T Cell Immunotherapy for Relapsed, Refractory CD 19+ Malignancy", Blood, (20121116), vol. 120, no. 21, page 756, XP055760298
OPPOSITION- Michael Kalos et al, "Sustained Functional T Cell Persistence and B Cell Aplasia Following CD 19-Targeting Adoptive T Cell Immunotherapy for Relapsed, Refractory CD 19+ Malignancy", Blood, (20121116), vol. 120, no. 21, page 756, XP055760298
OPPOSITION- Breslin S., "Cytokine-release syndrome: overview and nursing implications", Clinical Journal of Oncology Nursing, (20070101), vol. 11, no. 1 Suppl, doi:10.1188/07,CJmJ.S1.37-42, pages 37 - 42, XP055440000
OPPOSITION- BRESLIN S. et al., "Cytokine -Release Syndrome: Overview and Nursing Implications", Clin. J. of Onc. Nursing, (20070200), vol. 11, no. 1, pages 37 - 42, XP055440000
OPPOSITION- J S Du Bois, Et Al, "Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma", Journal of Clinical Oncology, American Society of Clinical Oncology, United States, United States, doi:10.1200/JCO.1997.15.3.1052, (19970301), pages 1052 - 1062, Journal of Clinical Oncology, URL: https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.1030.2878&rep=rep1&type=pdf, (20201217), XP055761070
OPPOSITION- James N. Kochenderfer et al, "Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US, (20150220), vol. 33, no. 6, doi:10.1200/JCO.2014.56.2025, ISSN 0732-183X, pages 540 - 549, XP055552252
OPPOSITION- SHEN et al., "Etanercept Restores the Antinociceptive Effect of Morphine and Suppresses Spinal Neuroinflammation in Morphine-Tolerant Rats", Anesthesia & Analgesia, (20110000), vol. 112, doi:10.1213/ANE.0b013e3182025b15, pages 454 - 459, XP055510432
OPPOSITION- Hao Hong Yiu, Andrea L. Graham, Robert F. Stengel, "Dynamics of a Cytokine Storm", PLoS ONE, vol. 7, no. 10, doi:10.1371/journal.pone.0045027, page e45027, XP055763358
OPPOSITION- Carlos A Ramos, Gianpietro Dotti, "Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy", Expert Opinion on Biological Therapy, (20110701), vol. 11, no. 7, doi:10.1517/14712598.2011.573476, ISSN 14712598, pages 855 - 873, XP055122639
OPPOSITION- RAMOS Carlos A. et al., "Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy", Expert Opin Biol Ther, (20120701), vol. 11, no. 7, pages 855 - 873, XP055122639
OPPOSITION- FUJIWARA K. et al., "Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold", Cells, (20200509), vol. 9, no. 5, page 1182, XP055760312
OPPOSITION- Martijn D. De Kruif, Et Al, "Prednisolone Dose-Dependently Influences Inflammation and Coagulation during Human Endotoxemia", The Journal of Immunology, American Association of Immunologists, US, US, (20070201), vol. 178, no. 3, doi:10.4049/jimmunol.178.3.1845, ISSN 0022-1767, pages 1845 - 1851, XP055763378
OPPOSITION- BRENNAN et al., "Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies", mAbs, (20100000), vol. 2, no. 3, doi:10.4161/mabs.2.3.11782, pages 233 - 255, XP055072297
OPPOSITION- David L Porter, Michael Kalos, Zhaohui Zheng, Bruce Levine, Carl June, "Chimeric Antigen Receptor Therapy for B-cell Malignancies", JOURNAL OF CANCER, Ivyspring International Publisher, AU, AU, (20110101), vol. 2042127, doi:10.7150/jca.2.331, ISSN 1837-9664, page 331, XP055247868
OPPOSITION- PORTER, D.L. et al., "Chimeric Antigen Receptor Therapy for B- cell Malignancies", J. Cancer, (20110601), vol. 2, pages 331 - 332, XP055247868
SEARCH- KEVIN J. CURRAN ET AL, "Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions", THE JOURNAL OF GENE MEDICINE, (20120627), vol. 14, no. 6, doi:10.1002/jgm.2604, ISSN 1099-498X, pages 405 - 415, XP055081970 [A] 1-12
SEARCH- GRAZYNA LIPOWSKA-BHALLA ET AL, "Targeted immunotherapy of cancer with CAR T cells: achievements and challenges", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, (20120422), vol. 61, no. 7, doi:10.1007/S00262-012-1254-0, ISSN 1432-0851, pages 953 - 962, XP035074376 [X] 1,3-9 * the whole document *
SEARCH- RENIER BRENTJENS ET AL, "Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial", MOLECULAR THERAPY, (20100401), vol. 18, no. 4, doi:10.1038/mt.2010.31, ISSN 1525-0016, pages 666 - 668, XP055143817 [Y] 2-10,12 * the whole document *
SEARCH- DAVID L. PORTER ET AL, "Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia", NEW ENGLAND JOURNAL OF MEDICINE, (20110825), vol. 365, no. 8, doi:10.1056/NEJMoa1103849, ISSN 0028-4793, pages 725 - 733, XP055052475 [A] 1-12
SEARCH- G. A. Yanik ET AL, "The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell", Blood, (20081015), pages 3073 - 3081, URL: http://www.bloodjournal.org/content/bloodjournal/112/8/3073.full.pdf, (20151215), XP055236431 [Y] 2-10,12 * the whole document *
SEARCH- J. N. KOCHENDERFER ET AL, "B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells", BLOOD, (20111208), vol. 119, no. 12, doi:10.1182/blood-2011-10-384388, ISSN 0006-4971, pages 2709 - 2720, XP055145503 [X] 1,3-9 * the whole document *
SEARCH- CARLOS A RAMOS ET AL, "Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy", EXPERT OPINION ON BIOLOGICAL THERAPY, (20110701), vol. 11, no. 7, doi:10.1517/14712598.2011.573476, ISSN 1471-2598, pages 855 - 873, XP055122639 [A] 1-12

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents